Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
1(25.0%)
Early Phase 1
1(25.0%)
4Total
N/A(2)
Phase 1(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04652219Early Phase 1Completed

CART Therapy in GUCY2C-positive Digestive Tract Tumors

Role: collaborator

NCT04780529Not ApplicableNot Yet Recruiting

CART Therapy in Digestive System Tumors

Role: lead

NCT03118180Phase 1Unknown

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Role: collaborator

NCT02813837Not ApplicableUnknown

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Role: lead

All 4 trials loaded